Author

Catherine Tak Piech

Observed names: C Piech, C. Piech, C. T. Piech, C. Tak Piech, C.T. Piech, Catherine Piech, Catherine T Piech, Catherine T. Piech, Piech, Catherine Tak

Institution: Janssen Scientific Affairs (United States)

Observed institutions: Cleveland Clinic, Schulman, Ronca & Bucuvalas, University of California San Diego, Wolters Kluwer Health, Abt Global (United States), Sandoz Group AG (Switzerland), Janssen Scientific Affairs (United States), Keymed Biosciences Inc. (China), ProgenaBiome (United States), The Ohio State University, Columbia University, Analysis Group (United States)

OpenAlex ID: A5113537447

Daily cost of an intensive care unit day: The contribution of mechanical ventilation*

2005 · Joseph F. Dasta, Trent P. McLaughlin, et al. · Critical Care Medicine · 886

Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference

2007 · Jakob B. Bjorner, Gene V. Wallenstein, et al. · Current Medical Research and Opinion · 174

Direct All-Cause Health Care Costs Associated With Chronic Kidney Disease in Patients With Diabetes and Hypertension: A Managed Care Perspective

2009 · Francois Laliberte, Brahim K. Bookhart, et al. · Journal of Managed Care Pharmacy · 73

PDF

Anaemia and the Risk of Injurious Falls in a Community-Dwelling Elderly Population

2008 · Mei Sheng Duh, Samir H Mody, et al. · Drugs & Aging · 53

Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review

2016 · Elaine Nguyen, Erin R. Weeda, et al. · Current Medical Research and Opinion · 48

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model

1996 · Albert Marchetti, Catherine Tak Piech, et al. · Clinical Therapeutics · 44

PDF

Disease and treatment burden of psoriasis: examining the impact of biologics.

2011 · Kalindi Raval, Jennifer H Lofland, et al. · PubMed · 30

Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia

2006 · Frank J. Papatheofanis, R. Scott McKenzie, et al. · Current Medical Research and Opinion · 30

Impact of limiting erythropoiesis‐stimulating agent use for chemotherapy‐induced anemia on the United States blood supply margin

2009 · Francis Vekeman, Brahim K. Bookhart, et al. · Transfusion · 28

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III

2009 · Edward C. Mansley, Norman V. Carroll, et al. · Value in Health · 26

Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review

2011 · David H. Henry, Corey J. Langer, et al. · Supportive Care in Cancer · 25

Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve

2005 · Mei Sheng Duh, Patrick Lefebvre, et al. · The Oncologist · 25

PDF

Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents

2005 · Tami L. Mark, R. Scott McKenzie, et al. · Current Medical Research and Opinion · 19

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations

2006 · Mei Sheng Duh, Samir H. Mody, et al. · Clinical Therapeutics · 18

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting

2007 · Francis Vekeman, R. Scott McKenzie, et al. · American Journal of Health-System Pharmacy · 17

Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: Results of a national internet-based survey

2010 · Susan C. Bolge, Heidi Waters, et al. · Clinical Therapeutics · 16

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations

2006 · Patrick Lefebvre, Antoine Gosselin, et al. · Current Medical Research and Opinion · 16

Outcomes and charges of elderly patients with acute myeloid leukemia

2006 · Laura M. Katz, Jamie B. Howell, et al. · American Journal of Hematology · 16

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia

2004 · Pierre Y. Cremieux, John M. Fastenau, et al. · Journal of Managed Care Pharmacy · 16

PDF

Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients

2010 · Francis Vekeman, Nadege-Desiree Yameogo, et al. · Journal of Medical Economics · 15

PDF

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia

2005 · R. Ben-Hamadi, M. S. Duh, et al. · Current Medical Research and Opinion · 15

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia

2011 · Chris L. Pashos, Kay Larholt, et al. · Supportive Care in Cancer · 14

PDF

Dose Conversion and Cost???Effectiveness of Erythropoietic???Therapies in Chemotherapy-Related Anaemia

2005 · James H Rosberg, Rym Ben-Hamadi, et al. · Clinical Drug Investigation · 14

Current Management of Anemia in Critically Ill Patients: Analysis of a Database of 139 Hospitals

2008 · Joseph Dasta, Samir H Mody, et al. · American Journal of Therapeutics · 13

Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa

2007 · Jeffrey Hymes, Tammy Bickimer, et al. · Current Medical Research and Opinion · 13

Works count: 100

Citation count: 1,777

H-index: 16

I10-index: 28